SciClone Pharmaceuticals (Holdings) Limited (6600.HK) Income Statement Analysis – Financial Results

About SciClone Pharmaceuticals (Holdings) Limited

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome. The company's pipeline products comprise Vibativ, a bactericidal, once-daily, injectable lipoglycopeptide antibiotic for the treatment of adult patients with hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/ leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic which treats solid tumors; PEN-866, a HSP90-binding miniature drug conjugate; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.